NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE · Drug Manufacturers - General · USD

Johnson & Johnson (JNJ) Stock Analysis

Johnson & Johnson (JNJ) is a Drug Manufacturers - General stock listed on NYSE and quoted in US Dollar.

JNJ

$275.23

−$3.20 (−1.15%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare JNJ with… →

JNJ Key Statistics

As of Sep 4, 2026
Trading
Open
$275.13
Previous Close
$278.43
Day's Range
274.75–277.80
52-Week Range
173.33–281.07
Volume
4.32M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.23
Valuation
Market Cap
$663.28B
P/E Ratio
31.97
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
22.36
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
4.44
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
6.77
EPS (ttm)Profit attributable to each share over the last twelve months.
8.61
Financials (FY)
Revenue (FY)
$94.19B+6.05%
Net Income (FY)
$26.80B+90.56%
Profit marginThe share of revenue left as profit after all costs and taxes.
21.48%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
2.41B
1-Year Return
+57.44%
Dividend and dates
Dividend
$5.36+1.93%
Ex-Dividend Date
August 25, 2026
Earnings Date
October 13, 2026
Avg Volume
7.85M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

JNJ Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+35.13%
2025+47.48%
2024−4.81%
2023−8.58%
2022+5.97%
2021+11.44%
2020+10.82%
2019+16.22%
2018−5.13%
2017+24.43%
2016 (partial year)−6.02%

As of September 4, 2026.

JNJ Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$94.19B$26.80B28.5%
2024$88.82B$14.07B15.8%
2023$85.16B$35.15B41.3%
2022$79.99B$17.94B22.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$94.19B$63.94B$25.60B$26.80B28.5%
2024$88.82B$61.35B$21.25B$14.07B15.8%
2023$85.16B$58.61B$22.01B$35.15B41.3%
2022$79.99B$55.39B$21.01B$17.94B22.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

JNJ Dividend History

$5.14+4.7% vs 2024

Dividends per share, 2025 · 4 payments

YearDividends per sharePaymentsChange
2026*$3.983—
2025$5.144+4.7%
2024$4.914+4.5%
2023$4.704+5.6%
YearDividends per sharePaymentsChange
2026 (partial year)$3.983—
2025$5.144+4.7%
2024$4.914+4.5%
2023$4.704+5.6%
2022$4.454+6.2%
2021$4.194+5.3%
2020$3.984+6.1%
2019$3.754+5.9%
2018$3.544+6.6%
2017$3.324+315.0%
2016$0.801—

Most recent payment: $1.33 per share, ex-dividend August 25, 2026. Per-share amounts summed by calendar year from ex-dividend dates. Partial years are shown muted and marked with an asterisk.

JNJ Valuation vs Drug Manufacturers - General Median

Median of 21 stocks
MetricJNJDrug Manufacturers - General medianvs median
P/E31.9724.6929% above
P/S ratio6.773.13116% above
Profit margin21.48%8.09%13.4 pts above

Medians across 21 Drug Manufacturers - General stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Johnson & Johnson (JNJ) is capitalised at $663.28B on the latest close. It is classified in the Drug Manufacturers - General industry, within the Healthcare sector. The company reports 138,200 employees.

JNJ last closed at $275.23 on September 4, 2026. That is −$3.20 (−1.15%) against the previous close. Over the past 52 weeks the price has ranged from $173.33 to $281.07. The latest close sits 58.79% above that 52-week low.

Financial Health

In fiscal 2025, Johnson & Johnson reported revenue of $94.19B. That is +6.05% against the prior fiscal year, when revenue was $88.82B. Net income for the same year was $26.80B. That is +90.56% against the prior fiscal year. Profit margin runs at 21.48%. That is 13.4 percentage points above the Drug Manufacturers - General median of 8.09%. Trailing earnings per share are 8.61.

Across the 4 fiscal years on file, revenue moves from $79.99B in 2022 to $94.19B in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

JNJ trades at a trailing price-to-earnings ratio of 31.97. That is 29.49% above the Drug Manufacturers - General median of 24.69. On forward earnings the ratio is 22.36. The PEG ratio, which sets the P/E against expected earnings growth, reads 4.44. The price-to-sales ratio is 6.77. On price-to-sales that is 116.28% above the Drug Manufacturers - General median of 3.13. 21 Drug Manufacturers - General companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 0.24. Daily returns over the trailing 10 years annualize to a volatility of 18.83%. The trailing one-year price return is +57.44%. Across 10 years the annualized return works out at +11.71%.

Growth & Income

JNJ pays a dividend yielding 1.93%. That is 0.8 percentage points below the Drug Manufacturers - General median yield of 2.7%. At the indicated rate that is $5.36 a share a year. The ex-dividend date on file is August 25, 2026. Dividends are recorded for 11 calendar years; 2026 shows 3 payments totalling $3.98 a share. The year before, 2025, totalled $5.14 a share.

The strongest complete calendar year on file is 2025 at +47.48%; the weakest is 2023 at −8.58%. Of the 9 complete calendar years on file, 6 finished higher. 2026 is still running; the price is +35.13% year to date.

Peer Comparison

Johnson & Johnson (JNJ) operates in the Drug Manufacturers - General industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Johnson & Johnson JNJ $663.28B 32.0
Eli Lilly and Company LLY $1.02T 38.6
AbbVie Inc. ABBV $453.19B 73.5
Merck & Co., Inc. MRK $370.89B 122.2

The Drug Manufacturers - General industry average P/E ratio is 24.7x. Johnson & Johnson trades at a P/E of 32.0.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - General Stocks

LLY

Eli Lilly and Company

$1.02T

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 NVS

Novartis AG

$304.10B

 AZN

AstraZeneca PLC

$252.33B

 AMGN

Amgen Inc.

$236.38B
View all Drug Manufacturers - General stocks →

Popular Healthcare Stocks

UNH

UnitedHealth Group Incorporated

$356.47B

 TMO

Thermo Fisher Scientific Inc.

$226.94B

 NVO

Novo Nordisk A/S

$206.02B

 ABT

Abbott Laboratories

$187.45B

 GILD

Gilead Sciences, Inc.

$187.23B
View all Healthcare stocks →

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Visit website →